GP
LLY icon

Geneva Partners’s Eli Lilly LLY Stock Holding History

Geneva Partners’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72M Sell
1,436
-3,683
-72% -$3.76M 0.46% 39
2026
Q1 		$4.71M Sell
5,119
-10,597
-67% -$10.7M 2.26% 21
2025
Q4 		$16.9M Buy
15,716
+12,984
+475% +$12.4M 6.01% 2
2025
Q3 		$2.08M Sell
2,732
-1,884
-41% -$1.4M 0.76% 33
2025
Q2 		$3.6M Buy
4,616
+33
+0.7% +$25.6K 1.43% 26
2025
Q1 		$3.79M Sell
4,583
-3,956
-46% -$3.29M 1.95% 20
2024
Q4 		$6.59M Sell
8,539
-182
-2% -$151K 2.68% 13
2024
Q3 		$7.73M Sell
8,721
-558
-6% -$502K 3.35% 11
2024
Q2 		$8.4M Buy
9,279
+1,021
+12% +$817K 3.46% 9
2024
Q1 		$6.42M Sell
8,258
-398
-5% -$283K 2.83% 12
2023
Q4 		$5.05M Sell
8,656
-428
-5% -$250K 2.8% 12
2023
Q3 		$4.88M Buy
9,084
+3,839
+73% +$1.98M 3.24% 12
2023
Q2 		$2.46M Buy
5,245
+1,653
+46% +$693K 1.6% 23
2023
Q1 		$1.23M Sell
3,592
-498
-12% -$168K 1.06% 34
2022
Q4 		$1.5M Buy
+4,090
New +$1.45M 1.41% 27
2022
Q2 		– Sell
-3,055
Closed -$875K – 68
2022
Q1 		$875K Buy
3,055
+1,555
+104% +$400K 0.54% 41
2021
Q4 		$414K Buy
+1,500
New +$380K 0.2% 77
2020
Q4 		– Sell
-30,075
Closed -$4.45M – 105
2020
Q3 		$4.45M Sell
30,075
-410
-1% -$63.5K 2.72% 11
2020
Q2 		$5M Buy
30,485
+5,450
+22% +$837K 3.51% 3
2020
Q1 		$3.47M Buy
+25,035
New +$3.44M 4.94% 5

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geneva Partners's LLY Position: Q2 2026 in Review

Geneva Partners reduced its Eli Lilly (LLY) stake by 72% in Q2 2026, selling an estimated $3.76M and leaving 1,436 shares worth $1.72M. The position accounts for 0.46% of the portfolio, ranked #39.

Geneva Partners first reported a position in LLY in Q1 2020 and has held it in 20 quarters since. The position peaked at $16.9M in Q4 2025. 4,632 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Geneva Partners held 1,436 shares of Eli Lilly worth $1.72M as of Q2 2026.
  • Geneva Partners sold 3,683 Eli Lilly shares in Q2 2026, an estimated $3.76M.
  • Eli Lilly made up 0.46% of Geneva Partners's portfolio in Q2 2026, its #39 holding.
  • Geneva Partners first reported a position in Eli Lilly in Q1 2020 and has held it in 20 quarters since.
  • Geneva Partners's Eli Lilly position peaked at $16.9M in Q4 2025.
  • 4,632 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Geneva Partners's 13F filing for Q2 2026, filed 10 Aug 2026.